Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Show more

Location: 245 Main Street, Cambridge, MA, 02142, United States | Website: https://immuneering.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

395.2M

52 Wk Range

$1.10 - $10.08

Previous Close

$6.25

Open

$6.12

Volume

125,401

Day Range

$6.10 - $6.32

Enterprise Value

390.6M

Cash

26.36M

Avg Qtr Burn

-12.88M

Insider Ownership

15.26%

Institutional Own.

35.53%

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
IMM-1-104 + Libtayo Details Cancer, Non-small cell lung carcinoma	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Atebimetinib (IMM-1-104) Details 1L Pancreatic cancer	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMM-1-104 + BRAF inhibitor Details Cancer, Melanoma	Phase 2a Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMM-1-104 + PD-1 inhibitor Details Cancer, Melanoma	Phase 2a Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMM-1-104 + G12C inhibitor Details Cancer, Non-small cell lung carcinoma	Phase 2a Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMM-6-415 Details Solid tumor/s	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.